Aurora’s Personalized CRISPR Ambition Hits Regulatory and Competitive Roadblocks

Aurora Therapeutics, launched in January 2026 with $16 million in seed funding, has abandoned its lead personalized CRISPR program for phenylketonuria (PKU) and reduced staff roughly seven months later.

The company was co-founded by CRISPR pioneer Jennifer Doudna and researcher Fyodor Urnov, whose work helped enable the first patient-specific CRISPR treatment for an infant known as Baby KJ.

Aurora’s goal was to make “one patient, one drug” therapies scalable by keeping most of the gene-editing system fixed and changing only the guide RNA for each mutation.

The company said it deprioritized PKU as competitors entered the same field. Beam Therapeutics announced a competing custom-editing program for PKU soon after Aurora launched.

Reporting also points to difficult FDA safety and manufacturing requirements, intellectual-property obstacles, and the high cost of repeatedly producing bespoke therapies.

Aurora’s setback does not indicate that personalized gene editing is unsafe or scientifically impossible. It highlights that the commercial, regulatory, manufacturing, and reimbursement model remains unproven.

It is not yet clear how many employees were laid off, whether Aurora will pursue another disease area, or whether its remaining leadership will stay.